
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇳🇿NZ · Entrepreneurship#191500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 ~2x weekly·13 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇳🇿100% - Active Followers
Loyal subscribers who consistently listen
200 to 1.2K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Panel: AI is a recompilation engine
Apr 7, 2026
Unknown duration
Hetti Barkworth-Nanton: Defence innovation is about protecting the vulnerable
Mar 24, 2026
Unknown duration
Brechtje Vreenegoor, Sebastiaan Berendse: In agriculture, spinouts need to reform the whole system
Mar 3, 2026
Unknown duration
Peter Devine: We never imagined Uniseed would be around this long
Feb 17, 2026
Unknown duration
Empowering academic founders: policies, programmes, and pitfalls
Sep 30, 2025
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4/7/26 | ![]() Panel: AI is a recompilation engine | Is AI about to steal your job? Today, we’re tackling the messy, complicated reality of generative AI, and asking a simple question: is it actually creating anything worthwhile? Sue Turner OBE and Richard Cole from the University of Bristol, Ben Ackland from Meaning Machine, and Megan Butler from KPMG aren’t here to wax poetic about robots. They’re staring down a terrifying trend: AI is being shoved into everything, often without the right frameworks in place. The result? A tidal wave of low-quality slop and a dangerous lack of oversight. Cole says AI is a “recompilation engine”, but he does have concrete examples of AI uses that deliver something new, with significant human input. This isn’t about fearmongering. It’s about asking: who controls the tools, and how do we stop AI from turning our creative industries into a bland echo chamber? This episode is a recording of the most recent Foresight Live event. Our next event, on 6 May, will tackle AI’s cybersecurity double-edged sword. Register here and join the Foresight newsletter here to hear about future events and handpicked stories about innovation from the University of Bristol. | — | ||||||
| 3/24/26 | ![]() Hetti Barkworth-Nanton: Defence innovation is about protecting the vulnerable | War in Ukraine. Conflict in the Middle East. Daily cyberattacks on critical infrastructure. As geopolitical tensions spike, capital is flooding into defence, and even a growing number of universities are open to research in this space. Yet, money invested in security innovation is money not spent on global aid. So should we really be doing this? Hetti Barkworth-Nanton says yes. As the CEO of Ploughshare Innovations, the commercialisation arm of the UK’s Ministry of Defence, she’s positioned at the heart of this debate. But her other role, chair of Refuge, a charity supporting domestic abuse survivors, throws a spanner into easy answers. How could a grenade ever be good for children? Hetti has a concrete, surprising example. We explore the uncomfortable tensions and unexpected synergies between securing nations and protecting the vulnerable. Is investment in defence research a zero-sum game with humanitarian aid? Or is there a more nuanced story about how technology, ethics, and institutional responsibility intersect? Hetti unpacks the philosophy behind commercialising defence innovation, why universities should engage with this space, and what it really means to balance competing goods in an uncertain world. | — | ||||||
| 3/3/26 | ![]() Brechtje Vreenegoor, Sebastiaan Berendse: In agriculture, spinouts need to reform the whole system | Wageningen University & Research is a truly unique organisation combining a higher education institution with an applied research institute. This dual nature makes commercialising research an interesting challenge, particularly with Wageningen’s focus on agtech and food tech, where, for decades, each component in the supply chain has been optimised for cost. So, how do you give spinouts a fighting chance? We also look at the Netherlands’ recent update to its national deal term principles, which Brechtje Vreenegoor was involved in creating, and we analyse how these principles strike a balance between the university’s interests and those of founders and investors. Then, we consider how Wageningen University & Research operates a unique pre-incubation programme designed to support researchers and students developing agricultural and food technology startups. This model focuses on validating ideas through a multi-stage process, including feasibility studies and proof-of-concept funding, rather than immediately seeking venture capital. And finally, Sebastiaan Berendse looks at Wageningen’s approach to venture capital funds, why its LP commitments are not just about capital but also drawing investors to campus, and why Graduate Ventures – which currently covers Delft and Rotterdam – is an enticing proposition for Wageningen’s ecosystem, which desperately needs more pre-seed cash. Read the transcript. | — | ||||||
| 2/17/26 | ![]() Peter Devine: We never imagined Uniseed would be around this long | At the end of last year, Uniseed CEO Peter Devine stepped down after two decades at the helm of a venture fund that has not only survived and thrived for a quarter of a century, but which has completely reshaped the Australian innovation ecosystem. It was a good excuse to sit down with Peter and reflect on how far the world of research commercialisation has come, what lessons have been learned, and what more remains to be done. We discuss how Uniseed convinced pension funds to invest decades ago (if you’re a policymaker in the UK: there’s actionable advice here), why governments getting involved in venture capital is a double-edged sword (Breakthrough Victoria will be an interesting case study when the dust has settled), and how former members of staff at Uniseed have gone on to help build a country where most universities have their own spinout investment fund. Candidly, Peter also shares tactical errors he made as CEO, and he explains how he turned a blockbuster exit that went from celebration to shock into an investment opportunity. And, of course, we find out what’s next for Peter. Spoiler: it’s not retirement. Read the transcript. | — | ||||||
| 9/30/25 | ![]() Empowering academic founders: policies, programmes, and pitfalls | How can universities instil the entrepreneurial mindset in faculty, staff and students? Is this even something you can teach? And if you can, what are some of the challenges and pitfalls? Figuring out the answers to these questions, and more, is a panel of experts from around the world: Kirsty Collinge, the head of research strategy at the University of Edinburgh; Linda Koschier, the head of entrepreneurship at the University of New South Wales’ Faculty of Engineering; Koenraad Debackere, the executive director of KU Leuven Research & Development; and Paul Cheek, a senior lecturer at the MIT Sloan School of Management. The panel will give insights into how you can empower students, how you can foster entrepreneurship on campus even if you live in a risk-averse culture, and how you can give people more time to focus on their business ideas. This episode is a recording of a TenU Hosts webinar, chaired by Catherine Headley, the CEO of the University of Manchester Innovation Factory. Further reading Paul Cheek mentions the book, From the Basement to the Dome, which offers an analysis of how MIT’s culture created a thriving entrepreneurial community. | — | ||||||
| 5/13/25 | ![]() Károly Szántó: Hungary will be the blueprint for university funds in Eastern Europe | There aren't many university venture funds in central and eastern Europe but that could all be about to change if Károly Szántó has his way. The COO of OUVC, the venture fund and studio set up by Óbuda University in Budapest, is working on a playbook that other institutions in the region can use to create their own venture capital funds, an interest Károly has identified at several universities. But his ambition goes beyond just sharing his expertise with other universities, he is also working to bring funds from Western European universities in as co-investors. Today on the podcast, we're heading to Hungary to find out how the ecosystem functions today, what's still missing, and why OUVC is about to split it into two separate entities. We also talk about Károly's own storied life, which includes work in 50 countries, finding his passion for university venturing when he first helped startups for a CVC, and what sailing across the Atlantic in 23 days taught him about startups. | — | ||||||
| 5/6/25 | ![]() Gavin Clark, Mark Mann: Here’s how to build a shared TTO | Towards the end of last year, the University of the Arts London secured a grant from Research England to lead a consortium of six universities that would develop a shared TTO focused on creative and social sciences. The pilot project, dubbed Shared Technology Transfer Office to Accelerate the Growth of Self-Funded Spinouts (STAGE), has now come to a close so it's the perfect time to reflect on what's gone well and what needs to happen next. Gavin Clark, director of enterprise and commercialisation at the University of the Arts London, and Mark Mann, a consultant who helped bring the consortium together, join me to explain why they used a model from the University of Birmingham to build their project, how that approach works, and what the pitfalls are of wrangling six universities to say “yes” to an external tech transfer office run by specialists from Kindling Ventures. We also explore the importance of capturing data (which will be made public in the coming weeks and months), how the project has drawn international attention and even what it's all meant on a more personal level. | — | ||||||
| 4/29/25 | ![]() Panel: What’s next for quantum technologies? | What does the future hold for quantum technologies, what are the pitfalls and how can academia, startups, industry and government work together to solve the challenges ahead? Earlier this month, I chaired a panel tackling these questions for Bristol Innovations' first Foresight Live event, featuring Ruth Oulton, professor of quantum photonics at the University of Bristol, Zoe Davidson, a research specialist in optical networks at telecoms firm BT, and Francesco Raffaelli, head of technology at secure communications startup KETS Quantum Security. I'm delighted to be able to share a full recording with you today. If you're interested in attending the next Foresight Live event, grab tickets here: https://www.eventbrite.co.uk/e/foresight-live-convergence-of-critical-technologies-in-ai-and-telecoms-tickets-1307798232719?aff=oddtdtcreator Make sure you also sign up for the newsletter Foresight Digest: https://biforesight.com/newsletter/ And if you'd rather watch the video of the panel, you can find that on BIForesight.com, where you can also find a a summary write-up by myself: https://biforesight.com/quantum/from-research-to-reality-quantum-is-not-ai/ | — | ||||||
| 4/15/25 | ![]() Nicky Dibben: People buy products, not technology | So, you've spun out of a university to sell your shiny new invention. How do you attract customers? You'll need a marketing strategy, which isn't a fancy way of saying “put ads on Google" or “post on social media". Rather, marketing is everything that comes between your company and your customer. It's the art of figuring out your value proposition (you have a technology, but what's the product?), of crafting messages that resonate with your customers and your investors (they're related but they must never be identical), and of evaluating markets to find traction. It will even help you decide whether you really should raise venture capital funding. Nicky Dibben runs Invention Marketing, helping deeptech founders build their marketing strategies. She's worked with NG Studios (an accelerator run by Northern Gritstone and Deeptech Labs for startups emerging out of the ecosystem around the universities of Leeds, Manchester and Sheffield). She's also a mentor for initiatives like Founders at the University of Cambridge. Nicky shares her experiences mentoring startups, comparing ecosystems in Cambridge and northern England, offers tangible advice for founders, and ponders how “product” has become king of the hill even though that's not the right focus. Find a copy of Nicky's marketing framework here: https://www.invention-marketing.co.uk/copy-of-services | — | ||||||
| 4/8/25 | ![]() Winsome Cheung: Startups, here’s what to know when negotiating with big pharma | If you've never been in a licensing negotiation, you might think big pharma always has the upper hand over startups desperate to get a deal done to secure licensing fees and milestone payments. Actually, these are two parties that share the same goal, and sometimes, a startup has a product so good it holds all the cards. But is it always straightforward? Deal negotiations between pharma companies and biotechs are the bread and butter of Winsome Cheung, a partner in the life sciences transaction group at global law firm Covington where she's represented clients on both sides of the table. Winsome — who, during her PhD in medicine, explored commercialising her research with Cambridge Enterprise — ponders how that experience went on to shape her thinking as a lawyer on today's episode of The Next Leap podcast. We also talk about industry trends she's observed in recent years, provisions in licensing contracts that could scupper M&A deals years down the line like exclusivity or reach-throughs, and why universities should have standardised templates in place for things like material transfer agreements. Let's nerd out over contract law! | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/1/25 | ![]() Stuart Wilkinson: What does a sweet shop have to do with spinouts? | Stuart Wilkinson, chief executive officer of Knowledge Exchange UK (the professional body for tech transfer practitioners in Britain), has personally experienced the myriad ways university research commercialisation can impact people's lives. It's given him a holistic view of the sector far beyond what his previous two decades focused on the University of Oxford might have you think. But while spinouts are the easiest story to tell, they're just a small piece of the commercialisation puzzle. The majority of university IP gets out into the world through licensing agreements and R&D collaborations with existing businesses, or through consulting. That means the economy needs to be thriving: businesses need both the cash and the workforce to forge these partnerships. Having rebranded from PraxisAuril earlier this year, Knowledge Exchange UK is ready to play an increasingly big role in shaping how research commercialisation is done. One example is its plan to help its members better collaborate on a regional level to share resources and solve problems in ways that account for and benefit their locality. The organisation is also looking to drive forward the professionalisation of the sector. Here, Stuart ponders a proposal from his former Oxford colleague Tom Hockaday, who recently called for a Master's degree in technology transfer… and why that means tech transfer is not unlike the evolution of the paramedics profession. | — | ||||||
| 3/25/25 | ![]() Erik Iverson, Mike Partsch: Industry doesn’t want newly hatched ideas | 2025 marks 100 years since the Wisconsin Alumni Research Foundation (WARF) became the first-ever tech transfer office. It's been a very successful first century for the non-profit organisation as we heard last week, but that does pose an interesting challenge: how can WARF keep innovating and make sure it not only survives but thrives for another 100 years? The organisation is certainly not resting on its laurels. WARF today is split into six verticals and much like you'd expect, many of them are groundbreaking. There is, for example, WARF Therapeutics, a drug development accelerator run by just a handful of people that has already brought tens of millions of additional grant funding to the University of Wisconsin-Madison campus. Today's guests are Erik Iverson, who became CEO of WARF in 2016 and brought with him a deep passion for life sciences, having earlier worked for the Bill and Melinda Gates Foundation and the Access to Advanced Health Institute. Also joining the show is Mike Partsch, WARF's inaugural chief venture officer who brought with him not only venture capital experience but also a deep understanding of tech transfer and spinouts: he founded the first-ever biotech spinout out of Penn in 1990 (which successfully IPO'd a few years later). | — | ||||||
| 3/18/25 | ![]() Kevin Walters: Vitamin D-fortified food changed universities forever | The story of technology transfer begins with Harry Steenbock's discovery of how to create vitamin D- fortified food. Steenbock, a professor of biochemistry at the University of Wisconsin-Madison, established the first-ever university tech transfer office not only to license his own invention to industry but also to support his colleagues present and future to do the same. This year, the Wisconsin Alumni Research Foundation (WARF) celebrates its 100th anniversary: https://www.warf.org/centennial/ But while WARF has forever changed how universities go about creating real-world applications for their research, it wasn't all smooth sailing: because WARF was created decades before the Bayh-Dole Act (which gives US universities the right to exploit their IP), there were several run-ins with the government, regulators and industry both at home and internationally. Kevin Walters wrote his PhD on the history of WARF and now serves as the organisation's public affairs associate. He explains why all of this could only have happened in a state known for its dairy industry and how Steenbock's childhood days on a farm meant he managed to do something that paediatricians did not. | — | ||||||
Showing 13 of 13
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.
